INTEGRATED BIOPHARMA, INC. (INBP) Return on equity 2019–2026
INTEGRATED BIOPHARMA, INC. (INBP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-16.1%FY2026 · since FY2019: 89.2% → -16.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -16.1% | -20.1 pp |
| FY2025 | 4.0% | +3.4 pp |
| FY2024 | 0.6% | +0.8 pp |
| FY2023 | -0.2% | -20.8 pp |
| FY2022 | 20.7% | -35.2 pp |
| FY2021 | 55.9% | -11.8 pp |
| FY2020 | 67.7% | -21.5 pp |
| FY2019 | 89.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross profitINBP Gross marginINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →